Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13253252 | 0.91 | HRH3 (0.39) | HRH3KCNH2EPHX2 | |
| SCHEMBL16376644 | 0.91 | HRH3 (0.39) | HRH3KCNH2EPHX2 | |
| SCHEMBL13890374 | 0.89 | HRH3 (0.38) | HRH3KCNH2CYP2D6 | |
| SCHEMBL25090324 | 0.88 | HRH3 (0.37) | HRH3KCNH2CYP2D6 | |
| SCHEMBL26497170 | 0.88 | ACHE (0.41) | HRH3 | |
| SCHEMBL23384367 | 0.88 | HRH3 (0.37) | HRH3 | |
| SCHEMBL24481136 | 0.88 | HRH3 (0.37) | HRH3 | |
| SCHEMBL11997995 | 0.86 | HRH3 (0.38) | HRH3KCNH2CHRNA7 | |
| SCHEMBL2737395 | 0.86 | HRH3 (0.38) | HRH3KCNH2CHRNA7 | |
| SCHEMBL2737413 | 0.86 | HRH3 (0.38) | HRH3KCNH2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240241099-A1 | METHOD FOR IDENTIFYING PI3 KINASE-ALPHA INHIBITORS | UNIVERSITÄT BASEL (CH) | 2024-07-18 | — | — | US | disclosed |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024076674-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024076670-A2 | TETHERED HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-4327886-A2 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | Libertas Bio, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| EP-1857459-A2 | Pyrazolopyrimidine compound and a process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-7285565-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-7271271-B2 | Imidazolo-related compounds, compositions and methods for their use | AMGEN SF, LLC (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070213361-A1 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | KYOWA KIRIN CO., LTD. (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070213361-A1 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | KYOWA KIRIN CO., LTD. (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070066586-A1 | ANILINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | HRH3 3552/4885KCNH2 2789/4885EPHX2 1575/4885 |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | TRPV1, TRPV5, TRPV2 | HRH3 335/4885KCNH2 531/4885EPHX2 2716/4885 |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | HRH3 2176/4885KCNH2 3575/4885EPHX2 850/4885 |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | HRH3 1065/4885KCNH2 4064/4885EPHX2 3112/4885 |
| US-20070066586-A1 | ANILINE DERIVATIVES | SERPINB1, ACE, REN | HRH3 206/4885KCNH2 120/4885EPHX2 1491/4885 |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | BRDT, BET1, BRD4 | HRH3 454/4885KCNH2 4663/4885EPHX2 2352/4885 |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | HRH3 4026/4885KCNH2 2357/4885EPHX2 173/4885 |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | KDM1A, TET1, KDM3A | HRH3 1048/4885KCNH2 1927/4885EPHX2 1919/4885 |
| US-20070213361-A1 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | MPO, MSR1, NR4A3 | HRH3 165/4885KCNH2 4107/4885EPHX2 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.